drugset / Trial / NCT05572476
Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Multicenter, prospective, open-labeled, 2-arm, randomized non-comparative (2:1) phase II trial assessing the efficacy of lurbinectedin in association with durvalumab
Timeline
- Start
- 2023-10
- Primary completion
- 2024-05-31
- Completion
- 2024-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Etoposide | Small molecule | — | Intravenous |
| Subject | Lurbinectedin | Other / unclassified | — | Intravenous |